HLA-B27 Testing: Laboratory Approach
Order HLA-B27 testing as a single blood test when evaluating for spondyloarthritis in patients with chronic back pain (>3 months, onset <45 years) or when inflammatory arthritis is suspected. 1, 2
Primary Laboratory Test
- HLA-B27 blood test is the only genetic test recommended for routine clinical use in this context
- This is a one-time test that does not need to be repeated 2
- Can be performed using flow cytometry or molecular methods (both acceptable) 3, 4
When to Order HLA-B27
The test is most useful in specific clinical scenarios:
- Chronic low back pain (>3 months duration) with onset before age 45 years 2
- Suspected spondyloarthritis based on clinical features 1
- Inflammatory back pain characteristics:
- Morning stiffness >30 minutes
- Pain at night/early morning
- Improvement with exercise 2
- Uveitis (ophthalmology has highest positive rate at 15.4%) 5
- Peripheral inflammatory arthritis when spondyloarthritis is in the differential 1
What NOT to Order Routinely
Avoid reflexive co-testing with other autoantibodies - despite 69.3% of clinicians ordering HLA-B27 alongside ANA, RF, and anti-CCP, this practice lacks evidence-based support 5. Order HLA-B27 as a targeted test based on clinical suspicion of spondyloarthritis, not as part of a broad autoimmune panel.
Do not order acute phase reactants (ESR/CRP) for screening purposes - these have only 50% sensitivity in ankylosing spondylitis and are inadequate screening tools 2. However, if ordered, note that HLA-B27-positive patients tend to have higher CRP levels (>1 mg/dL in 53% vs 0% in negatives) 6.
Test Performance Characteristics
- Sensitivity: 90% (misses only 10% of axial spondyloarthritis cases) 2
- Specificity: 90% 2
- Positive predictive value: Approximately 30-40% of HLA-B27-positive patients with chronic back pain will have axial spondyloarthritis 2
- Post-test probability: 32% (meaning 1 in 3 HLA-B27-positive patients with appropriate symptoms will have disease) 2
Important Caveats
Cross-reactivity exists with HLA-B7, HLA-B37, HLA-B39, HLA-B42, and HLA-B44 alleles, which can cause false positives with flow cytometry methods 7, 4. If positive by flow cytometry and clinical picture doesn't fit, confirm with molecular testing.
Not all HLA-B27 subtypes carry equal risk - HLA-B*27:06 is NOT associated with ankylosing spondylitis, while other subtypes are 3. Allele-level typing (second field resolution) provides better clinical interpretation but is not required for initial screening.
HLA-B27 is for screening, not diagnosis - the test increases pre-test probability but does not confirm disease 2. Approximately 8% of the general population is HLA-B27-positive without disease. Use clinical features and imaging (sacroiliac joint X-rays or MRI if available) for definitive diagnosis.
Clinical Action Based on Results
- If HLA-B27 positive: Refer to rheumatology for further evaluation 2
- If HLA-B27 negative: Consider alternative diagnoses, though 10% of spondyloarthritis patients are HLA-B27-negative 2
- Note that only 53% of HLA-B27-positive patients are currently referred to rheumatology, representing a significant care gap 5